| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.57 | 12.18 | 54.41 | 5.97 |
Op profit growth | 19.2 | 3.1 | 93.35 | -15.35 |
EBIT growth | 14.8 | -1.65 | 80.53 | -21.86 |
Net profit growth | -12.43 | -1.02 | 100.91 | -39.16 |
Profitability ratios (%) | ||||
OPM | 24.07 | 23.13 | 25.17 | 20.1 |
EBIT margin | 16.72 | 16.69 | 19.03 | 16.28 |
Net profit margin | 7.92 | 10.36 | 11.75 | 9.03 |
RoCE | 9.58 | 10.3 | 13.36 | 8.59 |
RoNW | 2.01 | 2.58 | 3.14 | 1.85 |
RoA | 1.13 | 1.59 | 2.06 | 1.19 |
Per share ratios (₹) | ||||
EPS | 6.43 | 7.05 | 7.26 | 7.55 |
Dividend per share | 0.5 | 0 | 0 | 1 |
Cash EPS | -1.38 | 0.21 | 1.63 | -0.21 |
Book value per share | 70.23 | 63.55 | 55.88 | 86.34 |
Valuation ratios | ||||
P/E | 52.02 | 57.98 | 37.27 | 39.35 |
P/CEPS | -242.25 | 1,931.33 | 165.67 | -1,403.62 |
P/B | 4.76 | 6.43 | 4.84 | 3.44 |
EV/EBIDTA | 19.95 | 27.01 | 19.37 | 34.63 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 16.11 |
Tax payout | -16.25 | -19.52 | -27.46 | -25.72 |
Liquidity ratios | ||||
Debtor days | 79.42 | 69.67 | 65.56 | 86.17 |
Inventory days | 92.87 | 84.37 | 61.86 | 60.09 |
Creditor days | -112.21 | -121.03 | -113.98 | -119.99 |
Leverage ratios | ||||
Interest coverage | -20.24 | -20.66 | -18.67 | -10.91 |
Net debt / equity | 0.4 | 0.32 | 0.25 | 0.18 |
Net debt / op. profit | 1.72 | 1.49 | 1.07 | 1.13 |
Cost breakup (₹) | ||||
Material costs | -33.21 | -31.41 | -32.23 | -39.67 |
Employee costs | -22.97 | -24.37 | -22.91 | -22.58 |
Other costs | -19.73 | -21.07 | -19.68 | -17.63 |
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Here are some of the stocks that may see significant price movement today: Hyundai Motor, Biocon, Zee Entertainment, etc.
Biocon has appointed Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India as lead advisors for the transaction
In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.
As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.
The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.
Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.
The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.
Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.
Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
